The Endomyocardial (Eosinophilic) Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Endomyocardial (Eosinophilic) Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Endomyocardial (Eosinophilic) Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Endomyocardial (Eosinophilic) Disease and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Endomyocardial (Eosinophilic) Disease by seven companies/universities/institutes. The top development phase for Endomyocardial (Eosinophilic) Disease is preclinical with five drugs in that stage. The Endomyocardial (Eosinophilic) Disease pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Endomyocardial (Eosinophilic) Disease pipeline products market are: PHAXIAM Therapeutics, iNtRON Biotechnology and Arietis.
The key targets in the Endomyocardial (Eosinophilic) Disease pipeline products market include 23S Ribosomal RNA, ATP Dependent Clp Protease Proteolytic Subunit Mitochondrial, and B Lymphocyte Antigen CD19.
The key mechanisms of action in the Endomyocardial (Eosinophilic) Disease pipeline product include Bacterial Cell Wall Disruptor with one drug in Phase I. The Endomyocardial (Eosinophilic) Disease pipeline products include four routes of administration with the top ROA being Intravenous and five key molecule types in the Endomyocardial (Eosinophilic) Disease pipeline products market including Biologic, and Small Molecule.
Endomyocardial (Eosinophilic) Disease overview
Eosinophilic endomyocardial disease is characterized by persisting blood eosinophilia and acute endocardial lesions that progress to endomyocardial fibrosis. In most cases the cause is unknown but it has been described in association with malignant tumors. The heart damage appears to be a direct result of tissue injury from toxic eosinophil granule proteins within the heart.
For a complete picture of Endomyocardial (Eosinophilic) Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
